Table 3.

Studies on the relationship between drugs acting on UA and their effects on CV diseases.

Study	No of Participants	Drugs Compared	Outcomes	Results	Reference
CARES	6198	Febuxostat vs. Allopurinol	4-component MACE (CV death, non-fatal MI, nonfatal stroke and unstable angina with urgent coronary revascularization)	Febuxostat is associated to a greater number of CV events	[73]
FAST	6128	Febuxostat vs. Allopurinol	Composite of hospitalization for non-fatal MI or biomarker-positive ACS; non-fatal stroke; CV death	Febuxostat is non-inferior to allopurinol	[74]
FREED	1070	Febuxostat vs. Other treatments	Composite of cerebral or cardiorenovascular events, all deaths	Febuxostat is associated to a redu-ction in renal events.	[76]
ALL-HEART	5938	Allopurinol vs. placebo	Composite of non-fatal MI, non-fatal stroke or CV death	On going	[77]
Huang et al.	100	Allopurinol vs. placebo	CV events	Allopurinol reduces inflammatory biomarkers and CV events	[78]

MACE: Major Adverse Cardiovascular Events.